featured
Chemotherapy De-Escalation Using an 18 F-FDG-PET–Based Pathological Response–Adapted Strategy in Patients With HER2-Positive Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology